Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 2(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02572492Phase 2Unknown

Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support

Role: lead

NCT02573935Phase 2Terminated

Clarithromycin in Multiple Myeloma Induction Therapy

Role: lead

NCT02109861Early Phase 1Unknown

Microdose Study of Melphalan, Bortezomib and Dexamethasone

Role: lead

NCT02624440Phase 2Unknown

Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma

Role: lead

All 4 trials loaded